Anthropic’s record US IPO, which raised about $81.3b and valued the AI group near $1.5t, has thrown a spotlight on how much capital is chasing artificial intelligence right now. That wave of interest reaches into British healthcare, where AI is being used to sharpen diagnosis, cut waiting lists and speed research. This article highlights three UK listed AI healthcare stocks from our screener that investors may want on their radar.
Those three stocks are just a sample from the idea, since the full screen also surfaced 6 more AI healthcare companies with equally compelling stories that are not covered below. To identify and analyze the rest of the field, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Overview: Poolbeg Pharma is a London based clinical-stage biopharma using AI driven discovery to develop therapies for infectious diseases and cancer.
Market Cap: £48.9 million
Investors looking at AI in healthcare may focus on Poolbeg Pharma’s AI program that screens drug candidates for influenza and respiratory syncytial virus. Its broader pipeline remains early stage and loss making. The attraction is that AI could compress years of trial-and-error in infectious disease research. The catch is what happens when a single key data readout shifts sentiment on that promise.
That kind of binary setup makes the next data point crucial, so it can be worth scanning the 2 warning signs (1 is major!) before sentiment flips on a single result.
Overview: IXICO runs AI enabled neuroimaging and imaging CRO services that help drug developers measure brain changes in neurological disease trials.
Operations: IXICO generates £7.3 million from Medical Labs & Research services, primarily through AI supported neuroimaging analytics for clinical studies.
Market Cap: £27.9 million
IXICO plugs AI directly into brain scans for Alzheimer’s, Huntington’s and Parkinson’s studies, turning complex imaging into decision ready biomarkers. The recent cerebral microbleed tool and late stage trial wins illustrate practical demand for that capability, while the group remains loss making. Future returns are influenced by how the expanding contract pipeline interacts with the current cost base.
That pressure on margins makes it worth checking the 1 key reward and 4 important warning signs (2 are major!) to see whether IXICO’s contract momentum could be masking either fragility or upside.
Overview: EMV Capital is a London based venture investor backing early to mid stage digital health, diagnostics and AI powered healthcare technologies.
Market Cap: £12.6 million
Pool capital into EMV Capital and you gain indirect exposure to AI driven diagnostics, wearables and remote monitoring, with earnings already positive and a P/E of 0.7x against a sector closer to 27x. The real test will be how one unseen pressure shapes cash returns from its AI healthcare portfolio.
That tension around an unseen pressure makes it worth pulling up the 3 key rewards and 2 important warning signs (1 is major!) to see how EMV Capital’s upside could be decoupling from headline earnings.
Fresh ideas do not sit still. Breakout moves, flying momentum and dropping entry windows get caught by those who act before the crowd. Scan new angles and get in early.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com